Cosibelimab Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5451-10mg

Add to Compare

Be the first to review this product

Cosibelimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG1 - lambda2

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

This product is a research-grade biosimilar of cosibelimab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not the clinical drug and is not intended for diagnostic or therapeutic use. Cosibelimab is a fully human IgG1 (lambda) monoclonal antibody directed against programmed death-ligand 1 (PD-L1, CD274). The originator, marketed as UNLOXCYT, received its first FDA approval in December 2024 for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. A distinguishing feature of cosibelimab relative to other PD-1/PD-L1 agents is that it retains a functional IgG1 Fc domain, giving it the potential to combine PD-L1 checkpoint blockade with antibody-dependent cell-mediated cytotoxicity (ADCC). This research-grade analog is manufactured to low endotoxin specifications (typically less than 1 EU/mg) and is available in bulk milligram-to-gram quantities, making it suitable as a functional reference standard and comparator in binding, blockade, and effector-function assays. Purity, isotype, and target engagement should be confirmed by the investigator for the specific application. PD-L1 (programmed death-ligand 1, also known as CD274 or B7-H1) is a type I transmembrane glycoprotein of the B7 immunoglobulin superfamily. It engages the inhibitory receptor PD-1 on activated T cells, and also binds B7.1 (CD80), delivering coinhibitory signals that dampen T-cell proliferation, cytokine production, and cytotoxic activity. PD-L1 is expressed on many immune and epithelial cell types and is frequently upregulated on tumor cells and within the tumor microenvironment, often in response to interferon-gamma, where it contributes to immune evasion. Blocking the PD-L1/PD-1 and PD-L1/B7.1 axes releases this inhibition and can restore anti-tumor T-cell responses, the rationale underlying checkpoint-blockade therapeutics. Because PD-L1 is a human target, agents against it are typically studied in human cell and tissue systems rather than in wild-type mouse models.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.